SEARCH:   Advanced

Blood, 1 July 2007, Vol. 110, No. 1, pp. 133-141. Prepublished online as a Blood First Edition Paper on March 19, 2007; DOI 10.1182/blood-2007-01-065995. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-01-065995v1 110/1/133    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Palumbo, J. S. Articles by Degen, J. L. Search for Related Content PubMed PubMed Citation Articles by Palumbo, J. S. Articles by Degen, J. L. Related Collections Hemostasis, Thrombosis, and Vascular Biology Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Tumor cell–associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell–dependent and–independent mechanisms Joseph S. Palumbo1, Kathryn E. Talmage2, Jessica V. Massari1, Christine M. La Jeunesse2, Matthew J. Flick2, Keith W. Kombrinck2, Zhiwei Hu3, Kelley A. Barney1, and Jay L. Degen2 Divisions of1 Hematology/Oncology and 2 Developmental Biology, Children's Hospital Research Foundation and the University of Cincinnati College of Medicine, Cincinnati, OH; 3 Yale University, New Haven, CT Tumor cell–associated tissue factor (TF) is a powerful determinant of metastatic potential. TF may increase metastasis by supporting thrombin-mediated proteolysis, through intracellular signaling events mediated by the TF cytoplasmic domain, through TF/fVIIa/fXa–mediated activation of protease-activated receptors, or through a combination of these processes. To better define the relationship between tumor cell-associated TF and circulating hemostatic factors in malignancy, we generated a set of C57Bl/6-derived tumor lines genetically lacking TF, expressing wild-type murine TF, or expressing a mutant TF lacking the cytoplasmic domain. Comparison of the metastatic potential of these cells in immunocompetent mice with genetic deficits in prothrombin, platelet function, or fibrinogen revealed that TF supports metastasis through mechanisms independent of the cytoplasmic domain, but dependent on each of these distal hemostatic factors. TF was neither required for primary tumor growth nor necessary for initial localization of embolized tumor cells within the lungs. Rather, tumor cell fate studies indicated TF supports metastasis by increasing the survival of micrometastases. One mechanism linking TF to metastasis is through a fibrin(ogen)-dependent and platelet-dependent restriction in natural killer cell–mediated clearance of micrometastases. However, TF also supported the early success of micrometastases through an additional mechanism independent of natural killer cells, but coupled to circulating prothrombin. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. M. Kuderer, T. L. Ortel, and C. W. Francis Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival J. Clin. Oncol., October 10, 2009; 27(29): 4902 - 4911. [Abstract] [Full Text] [PDF] R. S. Kasthuri, M. B. Taubman, and N. Mackman Role of Tissue Factor in Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4834 - 4838. [Abstract] [Full Text] [PDF] C. Boccaccio and P. M. Comoglio Genetic Link Between Cancer and Thrombosis J. Clin. Oncol., October 10, 2009; 27(29): 4827 - 4833. [Abstract] [Full Text] [PDF] H.-G. Kopp, T. Placke, and H. R. Salih Platelet-Derived Transforming Growth Factor-{beta} Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity Cancer Res., October 1, 2009; 69(19): 7775 - 7783. [Abstract] [Full Text] [PDF] M. Bezuhly, R. Cullen, C. T. Esmon, S. F. Morris, K. A. West, B. Johnston, and R. S. Liwski Role of activated protein C and its receptor in inhibition of tumor metastasis Blood, April 2, 2009; 113(14): 3371 - 3374. [Abstract] [Full Text] [PDF] Y. Rong, V. E. Belozerov, C. Tucker-Burden, G. Chen, D. L. Durden, J. J. Olson, E. G. Van Meir, N. Mackman, and D. J. Brat Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma through JunD/Activator Protein-1 Transcriptional Activity Cancer Res., March 15, 2009; 69(6): 2540 - 2549. [Abstract] [Full Text] [PDF] C. C. Milsom, J. L. Yu, N. Mackman, J. Micallef, G. M. Anderson, A. Guha, and J. W. Rak Tissue Factor Regulation by Epidermal Growth Factor Receptor and Epithelial-to-Mesenchymal Transitions: Effect on Tumor Initiation and Angiogenesis Cancer Res., December 15, 2008; 68(24): 10068 - 10076. [Abstract] [Full Text] [PDF] L. V. M. Rao and U. R. Pendurthi Sharing Tissue Factor: A Winning Strategy in Tumorigenesis Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1885 - 1886. [Full Text] [PDF] J. Yu, L. May, C. Milsom, G. M. Anderson, J. I. Weitz, J. P. Luyendyk, G. Broze, N. Mackman, and J. Rak Contribution of Host-Derived Tissue Factor to Tumor Neovascularization Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1975 - 1981. [Abstract] [Full Text] [PDF] H. H. Versteeg, F. Schaffner, M. Kerver, L. G. Ellies, P. Andrade-Gordon, B. M. Mueller, and W. Ruf Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T Mice Cancer Res., September 1, 2008; 68(17): 7219 - 7227. [Abstract] [Full Text] [PDF] H. H. Versteeg, F. Schaffner, M. Kerver, H. H. Petersen, J. Ahamed, B. Felding-Habermann, Y. Takada, B. M. Mueller, and W. Ruf Inhibition of tissue factor signaling suppresses tumor growth Blood, January 1, 2008; 111(1): 190 - 199. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020